Treatment of palmoplantar pustulosis with ustekinumab--the importance of interfering with the IL23/Th17 pathway.

Eur J Dermatol

Department of Dermatology, Hospital de Santo António-CHP, Rua D. Manuel II, s/n 4100 Porto, Portugal, Medical School, University of Porto, Porto, Portugal.

Published: February 2015

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2013.2196DOI Listing

Publication Analysis

Top Keywords

treatment palmoplantar
4
palmoplantar pustulosis
4
pustulosis ustekinumab--the
4
ustekinumab--the interfering
4
interfering il23/th17
4
il23/th17 pathway
4
treatment
1
pustulosis
1
ustekinumab--the
1
interfering
1

Similar Publications

Introduction: Palmoplantar psoriasis (PPp) has a profound negative impact on patients' quality of life, and it represents a therapeutic challenge, as palms and soles are difficult to treat area. Although the efficacy profile of tildrakizumab has been well evaluated in the literature, data on its use for PPp are still limited. The objective of the study was to evaluate the efficacy and safety of tildrakizumab on moderate-to-severe plaque psoriasis with involvement of the palmoplantar area.

View Article and Find Full Text PDF

Calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome, a systemic sclerosis subtype, features skin thickening, vascular issues, and organ involvement, causing complications in the gastrointestinal and musculoskeletal systems. Herein, we present a rare case of oral candidiasis, with CREST syndrome. The patient presented with xerostomia, tongue erythema, and burning pain.

View Article and Find Full Text PDF

parts of the world (1,2). CL is characterized by significant clinical variability. An ulcerated nodule on the exposed parts of the body (corresponding to the parasite inoculation site by the vector insect) is the classic presentation.

View Article and Find Full Text PDF

Immunotherapy, particularly that based on blocking checkpoint proteins in many tumors, including melanoma, Merkel cell carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast (TNB cancer), renal cancer, and gastrointestinal and endometrial neoplasms, is a therapeutic alternative to chemotherapy. Immune checkpoint inhibitor (ICI)-based therapies have the potential to target different pathways leading to the destruction of cancer cells. Although ICIs are an effective treatment strategy for patients with highly immune-infiltrated cancers, the development of different adverse effects including cutaneous adverse effects during and after the treatment with ICIs is common.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!